TARDBP and amyotrophic lateral sclerosis: The first report for therapeutic efficacy of CuII(atsm) in a mutant SOD1 mouse model of ALS provided evidence for the treatment decreasing cytoplasmic levels of phosphorylated TDP-43 [56].